Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The main objective of our study is to investigate the metabolic effects of a i) ordinary whey protein (WHE) and ii) a specific whey protein fraction (speWHE) when the interventions are ingested by patients with type 2 diabetes 30 minutes prior to an oral glucose tolerance test (OGTT). We will also investigate the glucose response when the patients ingest the interventions at home in their own environment 30 minutes before breakfast and dinner (2days) and also monitor glucose levels without interventions (2 days).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| WHE (regular whey protein) | Active Comparator | Regular whey protein. The intervention will be ingested 30 min. prior to an OGTT (3 hours). The intervention will also be ingested 30 min prior to breakfast and dinner for 2 days in the patient's own environment. |
|
| speWHE (specific whey protein compound) | Experimental | Specific whey protein compound. The intervention will be ingested 30 min. prior to an OGTT (3 hours). The intervention will also be ingested 30 min prior to breakfast and dinner for 2 days in the patient's own environment. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| speWHE | Dietary Supplement | 25 gram of a specific whey fraction (confidential) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Difference in iAUC for insulin between WHE and speWHE | Difference in iAUC for insulin between WHE and speWHE | OGTT, 3 hours. |
| Measure | Description | Time Frame |
|---|---|---|
| Differences in iAUC and concentration differences for GIP | OGTT 3 hours | |
| Differences in iAUC and concentration differences for GLP-1 | OGTT 3 hours | |
| Differences in iAUC and concentration differences for glucagon |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Niels Jessen, Professor | Medicinsk forskningslaboratorium for Diabetes og Hormonsygdomme og Steno Diabetes Center Aarhus (M-lab), Aarhus universitetshospital | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Medicinsk forskningslaboratorium for Diabetes og Hormonsygdomme og Steno Diabetes Center Aarhus (M-lab), Aarhus universitetshospital | Aarhus | Denmark |
Not provided
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
Double blinded, randomized, crossover design
Not provided
Not provided
Not provided
| WHE | Dietary Supplement | 25 gram protein of a regular whey compound |
|
| OGTT 3 hours |
| Differences in iAUC and concentration differences for glucose | OGTT 3 hours |
| Differences in iAUC and concentration differences for C-peptid | OGTT 3 hours |
| Differences in iAUC and concentration differences for FFA | OGTT 3 hours |
| Activity measurements | 5 days |
| continuous glucose measurement (CGM) | CGM with time in normal range 4-10 mmol/l, peak after a meal, AUC in the days with the interventions. | 5 days |
| D004700 | Endocrine System Diseases |